Cardiovascular risk is the chance of developing conditions that affect the heart and blood vessels, including coronary heart disease and stroke. It reflects more than one number. Age, blood pressure, cholesterol, diabetes, smoking, kidney health, family history, and other factors contribute, and their importance differs among people.
For women over 40, the menopause transition happens during years when cardiovascular risk factors may also change. The timing overlaps; that alone does not prove menopause is the sole cause. Age, health history, daily conditions, and reproductive aging can all be part of the picture.
What the evidence has established
Longitudinal research and the American Heart Association’s scientific statement describe average changes around the menopause transition in body composition, blood lipids, and measures of vascular health. These are meaningful risk-related findings, but they are not all cardiovascular events. A change in cholesterol or a vascular measurement is not the same outcome as a heart attack or stroke, and a group average cannot say what will happen to one person.
One UK cohort helps show why age and reproductive stage need to be considered together. Researchers followed cardiovascular measures over time in women who experienced natural menopause and compared groups at different stages. In that analysis, chronological age tracked carotid intima-media thickness more clearly than time since the final menstrual period. Reproductive age was associated with modest changes in fat mass and glucose. The study measured risk factors and a vascular marker, not heart attacks or strokes, and it cannot establish that menopause caused those changes.
This does not mean the transition is irrelevant. It means the evidence is more careful than a simple story in which menopause itself switches cardiovascular risk on. The Cardiovascular Health section of the Research Library summarizes the study population, findings, and limitations.
Earlier menopause and later cardiovascular outcomes
A systematic review and meta-analysis of observational studies found that women whose menopause began before age 45 had higher average rates of some later outcomes, including coronary heart disease and cardiovascular mortality, than women whose menopause began at age 45 or later. The included studies followed different populations and could not remove every possible influence, such as health and social factors that may relate both to menopause timing and later outcomes.
This is an association, not proof that earlier menopause caused a later event. It also does not give a personal risk estimate or mean that everyone with early menopause will develop cardiovascular disease. The distinction between a population pattern and an individual outcome matters whenever a study reports relative risk.
What remains under study
Researchers are examining vascular measures, menopause symptoms, and whether reproductive history could improve how cardiovascular risk is understood. These are developing lines of evidence. For example, reviews have reported associations between vasomotor or other menopausal symptoms and cardiovascular outcomes, but the findings rely on a small set of observational studies and weaken after accounting for established risk factors. A symptom pattern is not a cardiovascular diagnosis or a stand-alone forecast.
Likewise, a risk-factor change or a surrogate measure can help researchers ask what might be changing in a population. It does not, by itself, establish a cause, predict an event, or show that changing that measure will prevent one. Those questions require different kinds of evidence, including studies that assess clinical outcomes.
Where hormone therapy fits
Menopausal hormone therapy should not be presented as a way to prevent cardiovascular disease. The U.S. Preventive Services Task Force recommends against using menopausal hormone therapy for the primary prevention of chronic conditions in postmenopausal people. That recommendation is about prevention; decisions about treating menopause symptoms are a separate question and depend on individual context.
The wider midlife picture can feel connected without having one explanation. Read why everything seems to change at once and why your body can suddenly behave differently for more on overlapping changes. The earlier strength conversation explores another part of the same life stage.
Educational scope: This article is for general education. It cannot diagnose a condition or estimate your individual cardiovascular risk, and it is not individualized medical advice.
Source layer
These sources answer different questions. Scientific statements and observational studies describe patterns and associations; they do not establish that menopause alone causes cardiovascular disease or forecast an individual outcome.
- American Heart Association scientific statement: El Khoudary SR, et al. “Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention.” Circulation. 2020;142(25):e506–e532. This evidence synthesis reviews longitudinal research on the menopause transition, body composition, lipids, and vascular measures. It is not a clinical trial and cannot isolate menopause as the sole cause of cardiovascular risk changes. PubMed, PMID 33251828.
- Longitudinal cohort: Clayton GL, et al. “Cardiovascular health in the menopause transition: a longitudinal study of up to 3892 women with up to four repeated measures of risk factors.” BMC Medicine. 2022;20:299. The UK cohort analysis used repeated cardiovascular measures, including a natural-menopause group followed between mean ages 51 and 56. It found no strong association between time since the final menstrual period and carotid intima-media thickness beyond chronological age, alongside modest associations with fat mass and glucose. These were observational risk-factor and vascular-marker outcomes, not cardiovascular events, so the study cannot establish causation. PubMed, PMID 35974322.
- Systematic review and meta-analysis: Muka T, et al. “Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality.” JAMA Cardiology. 2016;1(7):767–776. The review pooled 32 observational studies involving 310,329 women. Menopause before age 45 was associated with higher rates of some outcomes, including coronary heart disease and cardiovascular mortality; observational evidence cannot show that earlier menopause caused those outcomes or remove all confounding. PubMed, PMID 27627190.
- Systematic review of symptoms and cardiovascular outcomes: Muka T, et al. “Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis.” PLoS ONE. 2016;11(6):e0157417. Ten observational studies included 213,976 women and 10,037 cardiovascular outcomes. The authors noted that adjusted associations were limited by potential unmeasured confounding and the small number of studies; symptoms are not established as a stand-alone individual prediction tool. PubMed, PMID 27315068.
- Prevention recommendation: U.S. Preventive Services Task Force. “Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions.” 2022. The recommendation advises against hormone therapy for primary prevention of chronic conditions in postmenopausal people; it addresses preventive use, not treatment of menopause symptoms. USPSTF recommendation.
Where to read next
For more midlife context, continue with why everything seems to change at once, why your body can suddenly behave differently, and the strength conversation to have earlier. Explore the Menopause guide, Metabolism & Body Composition guide, and the Research Library’s cardiovascular section for study details and limits.